Article
Oncology
Paul Nghiem, Shailender Bhatia, Evan J. Lipson, William H. Sharfman, Ragini R. Kudchadkar, Andrew S. Brohl, Philip A. Friedlander, Adil Daud, Harriet M. Kluger, Sunil A. Reddy, Brian C. Boulmay, Adam Riker, Melissa A. Burgess, Brent A. Hanks, Thomas Olencki, Kari Kendra, Candice Church, Tomoko Akaike, Nirasha Ramchurren, Michi M. Shinohara, Bob Salim, Janis M. Taube, Erin Jensen, Mizuho Kalabis, Steven P. Fling, Blanca Homet Moreno, Elad Sharon, Martin A. Cheever, Suzanne L. Topalian
Summary: In this study, the use of pembrolizumab in Merkel cell carcinoma patients showed a 58% overall response rate and a 39.1% 3-year progression-free survival rate. Patients with specific baseline factors and completion of 2 years of treatment were associated with better response and longer survival. Some patients experiencing disease progression or relapse following response had extended survival with salvage therapies including chemotherapies and immunotherapies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Chemistry, Medicinal
Yoichi Nishii, Kazuki Furuhashi, Kentaro Ito, Tadashi Sakaguchi, Yuta Suzuki, Kentaro Fujiwara, Taro Yasuma, Tetsu Kobayashi, Corina N. D'Alessandro-Gabazza, Esteban C. Gabazza, Osamu Taguchi, Osamu Hataji
Summary: This article reports a rare case of advanced thymic carcinoma that showed successful maintenance therapy with pembrolizumab after effective first-line treatment with carboplatin-based chemotherapy plus pembrolizumab. This provides a new approach for the treatment of thymic carcinoma.
Article
Gastroenterology & Hepatology
Chang Gon Kim, Chan Kim, Sang Eun Yoon, Kyung Hwan Kim, Seong Jin Choi, Beodeul Kang, Hye Ryun Kim, Su-Hyung Park, Eui-Cheol Shin, Yeun-Yoon Kim, Dae Jung Kim, Hyun Cheol Chung, Hong Jae Chon, Hye Jin Choi, Ho Yeong Lim
Summary: HPD can occur in a fraction of HCC patients treated with PD-1 inhibitors, leading to worse survival outcomes and missed treatment opportunities for the majority of affected patients. Analyzing baseline immune profiles and tumor growth dynamics during treatment could help identify HPD earlier for optimal patient management.
JOURNAL OF HEPATOLOGY
(2021)
Article
Oncology
Arielle Elkrief, Joao M. Victor Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R. Preeshagul, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe Lamberti, Jacklynn Egger, Jamie E. Chaft, Charles M. Rudin, Gregory J. Riely, Mark G. Kris, Marc Ladanyi, Yuan Chen, Matthew D. Hellmann, Ronglai Shen, Mark M. Awad, Adam J. Schoenfeld
Summary: This study compared the first-line efficacy of single-agent immunotherapy to chemotherapy combined with immunotherapy in patients with advanced lung adenocarcinoma. The results showed that chemotherapy combined with immunotherapy improved the objective response rate and progression-free survival in patients with tumor PD-L1 expression ≥1%. Among patients with PD-L1 expression ≥50%, never-smokers derived a better survival benefit from chemotherapy combined with immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Biochemistry & Molecular Biology
David Escors, Ana Bocanegra, Luisa Chocarro, Ester Blanco, Sergio Pineiro-Hermida, Maider Garnica, Leticia Fernandez-Rubio, Ruth Vera, Hugo Arasanz, Grazyna Kochan
Summary: PD-L1/PD-1 blockade immunotherapy has revolutionized cancer treatment, but its mechanisms and effectiveness are still not fully understood. This article reviews the evidence supporting the role of CD4 T cells in anti-tumor immunity and their potential as predictors of response to PD-L1/PD-1 blockade immunotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, General & Internal
V Makker, N. Colombo, A. Casado Herraez, A. D. Santin, E. Colomba, D. S. Miller, K. Fujiwara, S. Pignata, S. Baron-Hay, I Ray-Coquard, R. Shapira-Frommer, K. Ushijima, J. Sakata, K. Yonemori, Y. M. Kim, E. M. Guerra, U. A. Sanli, M. M. McCormack, A. D. Smith, S. Keefe, S. Bird, L. Dutta, R. J. Orlowski, D. Lorusso
Summary: Lenvatinib plus pembrolizumab significantly prolongs progression-free survival and overall survival compared to chemotherapy in advanced endometrial cancer patients.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Hematology
Matthew Mei, Lu Chen, James Godfrey, Joo Song, Colt Egelston, Sandrine Puverel, Elizabeth Budde, Saro Armenian, Liana Nikolaenko, Mary Nwangwu, Weihua Guo, Lei Gao, Peter Lee, Robert Chen, Shari Daniels, Neena Kennedy, Lacolle Peters, Jasmine Zain, Steven Rosen, Stephen Forman, Leslie Popplewell, Larry Kwak, Alex F. Herrera
Summary: This phase 1 study evaluated the addition of vorinostat to pembrolizumab in patients with follicular lymphoma. The study found that the combination therapy had a high overall response rate in patients with relapsed classical Hodgkin's lymphoma.
Article
Oncology
Lisa May Ling Tachiki, Daniel S. Hippe, Karly Williams Silva, Evan Thomas Hall, William Mccamy, Dane Fritzsche, Andrea Perdue, Julia Majovski, Thomas Pulliam, Daniel A. Goldstein, Joshua Veatch, Joel Ho, Paul T. Nghiem, John A. Thompson, Shailender Bhatia
Summary: The optimal duration of treatment with immune checkpoint inhibitors (ICI) in metastatic cancers is still unclear. Many patients develop progressive disease after discontinuation of ICI. A reduced frequency dosing (RFD) approach may be a more practical and economically viable option to extend treatment duration.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Pharmacology & Pharmacy
Mengjie Wang, Yu Bai, Jiaxin Pei, Dongqing Li, Xiaolin Pu, Wenyu Zhu, Lei Xia, Chunjian Qi, Hua Jiang, Yongling Ning
Summary: This study evaluated the use of whole glucan particle (WGP) beta-glucan in combination with PD-1/PD-L1-blocking antibodies. Results showed that this combination therapy increased immune cell recruitment, improved the balance between T-cell activation and immune tolerance, and delayed tumor progression. Additionally, it improved progression-free survival in advanced cancer patients.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
A. G. Leone, F. Petrelli, A. Ghidini, A. Raimondi, E. C. Smyth, F. Pietrantonio
Summary: Immunotherapy-based regimens show clear survival benefits compared to chemotherapy alone in patients with advanced esophageal squamous cell carcinoma. The efficacy is not dependent on geographical region or treatment line. The programmed death-ligand 1 CPS status is associated with the treatment's effectiveness.
Article
Oncology
Ivelina Spassova, Selma Ugurel, Linda Kubat, Lisa Zimmer, Patrick Terheyden, Annalena Mohr, Hannah Bjorn Andtback, Lisa Villabona, Ulrike Leiter, Thomas Eigentler, Carmen Loquai, Jessica C. Hassel, Thilo Gambichler, Sebastian Haferkamp, Peter Mohr, Claudia Pfoehler, Lucie Heinzerling, Ralf Gutzmer, Jochen S. Utikal, Kai Horny, Hans-Ulrich Schildhaus, Daniel Habermann, Daniel Hoffmann, Dirk Schadendorf, Juergen Christian Becker
Summary: This multicenter retrospective study of 114 unresectable MCC patients examined clinical and molecular characteristics to identify factors associated with a favorable response to PD-1/PD-L1 ICI therapy. Findings highlighted the absence of immunosuppression, limited number of tumor-involved organs, and a predominance of CD8(+) T-CM among TIL as key baseline parameters influencing therapy response in advanced MCC patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Immunology
Joseph Mabbitt, Ian D. Holyer, James A. Roper, Ulf J. Nilsson, Fredrik R. Zetterberg, Lynda Vuong, Alison C. Mackinnon, Anders Pedersen, Robert J. Slack
Summary: This study found that Gal-3 can enhance the PD-1/PD-L1 immune axis and potentially contribute to immunosuppressive signaling mechanisms within the tumor microenvironment. Additionally, Gal-3 prevents atezolizumab and pembrolizumab from engaging with their respective immune checkpoint receptors. Reversal of this effect with the clinical candidate GB1211 offers a potential enhancing combination therapeutic with anti-PD-1 and -PD-L1 blocking antibodies.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, General & Internal
Andrea Cercek, Melissa Lumish, Jenna Sinopoli, Jill Weiss, Jinru Shia, Michelle Lamendola-Essel, Imane H. El Dika, Neil Segal, Marina Shcherba, Ryan Sugarman, Zsofia Stadler, Rona Yaeger, J. Joshua Smith, Benoit Rousseau, Guillem Argiles, Miteshkumar Patel, Avni Desai, Leonard B. Saltz, Maria Widmar, Krishna Iyer, Janie Zhang, Nicole Gianino, Christopher Crane, Paul B. Romesser, Emmanouil P. Pappou, Philip Paty, Julio Garcia-Aguilar, Mithat Gonen, Marc Gollub, Martin R. Weiser, Kurt A. Schalper, Luis A. Diaz
Summary: This study found that mismatch repair-deficient, locally advanced rectal cancer is highly sensitive to PD-1 blockade. Additionally, no adverse events of grade 3 or higher have been reported, and no cases of progression or recurrence have been observed. Longer follow-up is needed to assess the duration of response.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Chang Gon Kim, Moonki Hong, Hei-Cheul Jeung, Garden Lee, Hyun Cheol Chung, Sun Young Rha, Hyo Song Kim, Choong-kun Lee, Ji Hyun Lee, Yejeong Han, Jee Hung Kim, Seo Young Lee, Hyunki Kim, Su-Jin Shin, Song-Ee Baek, Minkyu Jung
Summary: This study investigated the occurrence and clinical implications of hyperprogressive disease (HPD) in patients with advanced gastric cancer (AGC) treated with PD-1 inhibitors. The results showed that patients with HPD had shorter progression-free survival and overall survival, losing opportunities for subsequent treatments. Hypoalbuminemia was significantly associated with the occurrence of HPD and inferior survival outcomes.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Charles Lance Cowey, Frank X. Liu, Ruth Kim, Marley Boyd, Nicole Fulcher, Stan Krulewicz, Vijay Kasturi, Abhijeet Bhanegaonkar
Summary: Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer that progresses quickly, leading to poor prognosis for many patients. Avelumab, the first drug approved by the US FDA for treating metastatic MCC, helps the patient's immune system fight cancer. The study showed that patients with locally advanced and metastatic MCC treated with first-line avelumab in a real-world setting experienced comparable response rates and survival benefits.
Letter
Dermatology
Kevin A. Nguyen, Nolan J. Maloney, Allene Fonseca, Paul Nghiem, Lisa C. Zaba
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2022)
Letter
Dermatology
Ulla Kring Hansen, Rikke Lyngaa, Dafina Ibrani, Candice Church, Monique Verhaegen, Andrzej Antoni Dlugosz, Jurgen Christian Becker, Per Thor Straten, Paul Nghiem, Sine Reker Hadrup
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Review
Dermatology
Tomoko Akaike, Paul Nghiem
Summary: Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer with challenging management. MCC can be caused by Merkel cell polyomavirus and ultraviolet-induced mutations, both of which are highly immunogenic, enabling diverse T-cell targeted therapies. Recent progress includes remarkable improvement in the prognosis of advanced MCC patients through the use of PD-1 pathway blocking agents. Additionally, the management and prognosis of early-stage MCC have improved with better integration of surgery and radiotherapy and advanced liquid biopsies for early detection.
JOURNAL OF DERMATOLOGICAL SCIENCE
(2022)
Meeting Abstract
Genetics & Heredity
Devin Hunt, Noreen Mohsin, Paul Nghiem, Morgan Similuk, Bryce Seifert, Rajarshi Ghosh, Isaac Brownell, Magdalena Walkiewicz-Yvon
GENETICS IN MEDICINE
(2022)
Article
Dermatology
Aubriana M. McEvoy, Kristina Lachance, Daniel S. Hippe, Kelsey Cahill, Yasman Moshiri, Christopher W. Lewis, Neha Singh, Song Y. Park, Zoe Thuesmunn, Maclean M. Cook, Nora A. Alexander, Lauren Zawacki, Hannah Thomas, Kelly G. Paulson, Paul Nghiem
Summary: This study aimed to estimate the risk of stage-specific MCC recurrence and mortality since diagnosis. The study included 618 MCC patients enrolled in a Seattle-based data repository from 2003 to 2019. The results showed a 5-year recurrence rate of 40% for MCC, with 95% of recurrences occurring within the first 3 years.
Meeting Abstract
Dermatology
Thomas H. Pulliam, Rashmi Bhakuni, Saumya Jani, Kimberly Smythe, Brandon Seaton, Lisa Tachiki, Rima Kulikauskas, Paul Nghiem, Shailender Bhatia
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Meeting Abstract
Dermatology
Shira Tabachnick-Cherny, Thomas Pullliam, Kimberly Smythe, Paul Nghiem
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Meeting Abstract
Dermatology
Lisa M. Tachiki, Lauren Zawacki, Daniel S. Hippe, Yasman Moshiri, Nora Alexander, Tomoko Akaike, Coley Doolittle-Amieva, Thomas Pulliam, Lisa C. Zaba, Shailender Bhatia, Paul Nghiem
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Meeting Abstract
Dermatology
Joshua Veatch, Kelly Paulson, Yuta Asano, Megan McAfee, Lauren Martin, Bo Lee, Evan Hall, Shailender Bhatia, Paul Nghiem, Aude Chapuis
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Meeting Abstract
Dermatology
Tomoko Akaike, Naomi So, Daniel S. Hippe, Lindsay Gunnell, Coley Doolittle-Amieva, Kristina Lachance, Evan Hall, Shailender Bhatia, Alec Eschholz, Richa Rathore, Nicole Hook, Kathryn Baker, Angel Rodriguez, Andrew Ecklund, Alexey Aleshin, Paul Nghiem, Lisa C. Zaba
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Meeting Abstract
Dermatology
Tomoko Akaike, Naomi So, Daniel S. Hippe, Lindsay Gunnell, Coley Doolittle-Amieva, Kristina Lachance, Evan Hall, Shailender Bhatia, Alec Eschholz, Richa Rathore, Nicole Hook, Kathryn Baker, Angel Rodriguez, Andrew Ecklund, Alexey Aleshin, Paul Nghiem, Lisa C. Zaba
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Meeting Abstract
Dermatology
Wenwen Chen, Shailender Bhatia, Andrew S. Brohl, Sunandana Chandra, Sumia Dakhil, Leslie A. Fecher, Ling Gao, Ted A. Gooley, Glenn J. Hanna, Reina Hibbert, Ciara M. Kelly, Samantha M. Kiriluk, Karl Lewis, Stergios Moschos, Paul Nghiem, John A. Thompson, Scott S. Tykodi
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Meeting Abstract
Dermatology
S. Y. Park, D. Hippe, L. Zawacki, M. Bierma, S. Bhatia, L. Zaba, P. Nghiem, N. Singh
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Meeting Abstract
Oncology
Lisa May Ling Tachiki, Karly Williams Silva, Daniel S. Hippe, Dane Fritzsche, Aleksandra Raczka, Andrea Perdue, Julia Majovski, Alexandra Spallone, Daniel A. Goldstein, Paul Nghiem, John A. Thompson, Evan Thomas Hall, Shailender Bhatia
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Joshua Veatch, Kelly Paulson, Yuta Asano, Lauren Martin, Bo Lee, Evan Thomas Hall, Shailender Bhatia, Paul Nghiem, Aude Chapuis
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)
